Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

CONTEXT: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substa...

Full description

Bibliographic Details
Main Authors: Chortis, V, Taylor, A, Schneider, P, Tomlinson, J, Hughes, B, O'Neil, D, Libé, R, Allolio, B, Bertagna, X, Bertherat, J, Beuschlein, F, Fassnacht, M, Karavitaki, N, Mannelli, M, Mantero, F, Opocher, G, Porfiri, E, Quinkler, M, Sherlock, M, Terzolo, M, Nightingale, P, Shackleton, C, Stewart, P, Hahner, S, Arlt, W
Format: Journal article
Language:English
Published: 2013

Similar Items